Our cell data demonstrated that GRK5-IN-2 treatment resulted in decreased and/or delayed adipogenesis much like our GRK5 KO cell line, as well as decreased de novo lipogenesis (Fig. 5), suggesting that GRK5 inhibition may be a therapeutic target for treating and preventing obesity. This evidence concerns the gene GRK5 and obesity due to melanocortin 4 receptor deficiency.